TABLE 1.
Baseline characteristics of study participants
| Patient ID | Age (yr) | Gendera | HIV-1 RNA (copies/ml) | Baseline CD4+ T cells (cells/mm3) | Viral tropism | ART duration (mo) | Regimenb |
|---|---|---|---|---|---|---|---|
| MTS 1 | 58 | M | <37 | 390 | R5 | 118 | TDF/FTC/EFV |
| MTS 2 | 52 | M | <37 | 908 | R5 | 76 | ABC/3TC/EFV |
| MTS 3 | 50 | M | <37 | 792 | Indeterminate | 53 | TDF/FTC/EFV |
| MTS 4 | 35 | F | <37 | 641 | R5 | 36 | TDF/FTC/EFV |
| MTS 5 | 67 | M | <37 | 380 | Non-R5 | 138 | TDF/FTC/EFV |
| MTS 6 | 51 | M | <37 | 394 | R5 | 156 | TDF/FTC/EFV |
| MTS 7 | 58 | M | <37 | 1,147 | Indeterminate | 169 | ABC/3TC/ATV |
| MTS 8 | 72 | M | <37 | 794 | Non-R5 | 181 | ABC/3TC/ATVr |
| MTS 9 | 29 | M | <37 | 526 | Indeterminate | 51 | TDF/FTC/EFV |
| MTS 10 | 52 | M | <37 | 907 | R5 | 106 | TDF/FTC/EFV |
| MTS 11 | 44 | M | <37 | 788 | R5 | 95 | ABC/3TC/ATV |
| MTS 12 | 41 | M | <37 | 686 | R5 | 206 | ABC/3TC/NVP |
| MTS 13 | 54 | M | <37 | 517 | R5 | 137 | TDF/FTC/EFV |
| MTS 14 | 52 | M | <37 | 461 | R5 | 92 | TDF/FTC/RPV |
| MTS 15 | 42 | M | <37 | 400 | R5 | 23 | TDF/FTC/RPV |
| MTS 16 | 34 | M | <37 | 888 | R5 | 23 | TDF/FTC/RPV |
| MTS 17 | 43 | M | <37 | 399 | Indeterminate | 210 | TDF/3TC/ATVr |
| MTS 18 | 49 | M | <37 | 741 | R5 | 221 | ABC/3TC/EFV |
| MTS 19 | 44 | M | <37 | 740 | Non-R5 | 194 | TDF/FTC/RPV |
| MTS 20 | 50 | M | <37 | 456 | Non-R5 | 170 | TDF/FTC/EFV |
| Median (IQR) | 49 (42.5–51) | <37 | 664 (414.6–794.2) | 127.5 (58.7–181) |
a
M, male; F, female.
b
3TC, lamivudine; ABC, abacavir; ATV, atazanavir; ATVr, ritonavir-boosted atazanavir; EFV, efavirenz; FTC, emtricitabine; NVP, nevirapine; RPV, rilpivirine; TDF, tenofovir disoproxil fumarate.